Full Funding Of Indirect Costs, Other Mandates By Congress Chew Up Most Of NCI’s Extra Money
In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List
Five Year Survival Up To 48 Percent; DeVita Has “No Doubt” It Is Really Over 50 Percent Now
Cooperative Group Chairman Unhappy Over Exclusion From Funding at Recommended Levels
Workshop Calls For Improved Surgical Oncology Training Programs
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field
- The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer. - Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish
